Medical devices producer Abbott has received CE Mark approval for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System in Europe.
Xience Xpedition 48 uses the design and clinical outcomes of the Xience family of drug eluting stents in 48mm length to treat very long blockages in the vessels that supply blood to the heart due to the coronary artery disease (CAD).
The Xience Xpedition 48 eluting coronary stent is expected to minimise the use of devices, exposure to X-ray during the procedure, and procedure time, leading to economic benefits.
Maasstad Ziekenhuis Netherlands MD Peter Smits said with global economic pressures impacting hospitals and health care systems around the world, products like Xience Xpedition 48 may provide important cost savings to the system.
"I believe that this new treatment option, backed by the robust clinical outcomes of the XIENCE family of drug eluting stents, will help physicians in the treatment of long lesions," Smits added.
Xience Xpedition 48 is supported by strong clinical evidence from the Xience family of drug eluting stents, including data from more than 53,000 patients across more than 100 studies with long-term outcomes out to five years, according to the company.
Abbott Vascular Medical Affairs and chief medical officer divisional vice president Charles Simonton said, "XIENCE Xpedition 48 provides a new, unique solution for treating patients with very long lesions, affirming Abbott’s commitment to continued innovation."